258513-41-6

Basic information

• Product Name: 2,5-DIFLUOROPHENACYL BROMIDE
• Synonyms: 2,5-DIFLUOROPHENACYL BROMIDE;2-BROMO-2',5'-DIFLUOROACETOPHENONE;2-Bromo-1-(2,5-difluorophenyl)ethanone;2-Bromo-2',5'-difluoroacetophenone, 2-Bromo-1-(2,5-difluorophenyl)ethan-1-one;Ethanone, 2-broMo-1-(2,5-difluorophenyl)-
• CAS NO: 258513-41-6
• Molecular Formula: C₈H₅BrF₂O
• Molecular Weight: 235.03
• Product Categories: Benzene series
• Mol File: 258513-41-6.mol

Chemical Properties

• Melting Point: 37-40
• Boiling Point: 245.8 °C at 760 mmHg
• Flash Point: 102.4 °C
• Appearance: /
• Density: 1.648 g/cm³
• Storage Temp.: 2-8°C
• Solubility: DCM, Methanol
• CAS DataBase Reference: 2,5-DIFLUOROPHENACYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIFLUOROPHENACYL BROMIDE(258513-41-6)
• EPA Substance Registry System: 2,5-DIFLUOROPHENACYL BROMIDE(258513-41-6)

Safety Data

• Hazard Codes: C,F
• Hazardous Substances Data: 258513-41-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,5-Difluorophenacyl Bromide is used as an intermediate in the synthesis of Isavuconazole (I777830), a triazole-based antifungal agent. It is particularly effective in the treatment of invasive fungal infections, which are a significant concern in immunocompromised patients and those with underlying health conditions. The compound's role in the production of Isavuconazole highlights its importance in addressing the growing need for effective antifungal therapies.
In the synthesis process, 2,5-Difluorophenacyl Bromide serves as a key building block for the formation of the final antifungal drug. Its unique molecular structure allows for the creation of the desired pharmacophore, which is essential for the drug's activity against various fungal pathogens. By facilitating the development of Isavuconazole, 2,5-Difluorophenacyl Bromide contributes to the advancement of antifungal treatments and helps combat the increasing prevalence of drug-resistant fungal infections.

Upstream product

• 1979-36-8 2',5'-difluoroacetophenone 

Downstream Products

• 1027527-46-3 8-benzoyl-2-(2,5-difluoro-phenyl)-6,7,8,9-tetrahydro-5H-1,3a,5,8-tetraaza-cyclopenta[a]naphthalen-4-one 
• 857842-94-5 5,6-dimethyl-3-amino-2-(2',5'-difluorobenzoyl)-thieno[2,3-b]pyridine 
• 857842-92-3 2-(2,5-difluorobenzoyl)-5-methoxybenzofuran 
• 934340-23-5 C₁₂H₉F₂NO₃ 
• 71682-96-7 3-(2,5-difluorophenyl)-3-oxopropanenitrile 

Relevant articles and documents

Microwave-assisted synthesis and luminescent activity of imidazo[1,2-a]pyridine derivatives

In this work, a series of phenacyl bromide derivatives was synthesized and employed as key intermediate for the synthesis of substituted imidazo[1,2-a]pyridines. First, phenacyl bromide molecules were obtained from the bromination reaction of acetophenones assisted by microwave irradiation, obtaining the products 4a-v in a 15 minutes reaction with yields in the range of 50% to 99%. Subsequently, the conjugation of these molecules with 2-aminopyridine conduced to the production of imidazo[1,2-a]pyridine derivatives (7a-v) in a 60-second reaction with yields of 24% to 99%. Improved yields were determined with respect to those obtained with more tedious methodologies like thermally and mechanically assisted routes. Intense luminescence emissions in the purple and blue regions of the electromagnetic spectra were observed under UV excitation according to the nature of the substituents. This environmentally friendly methodology is expected to constitute an important class of organic compounds for the development of biomarkers, photochemical sensors, and medicinal applications.

3-Substituted-(5-arylfuran-2-ylcarbonyl)guanidines as NHE-1 inhibitors

The C-3 substituents effect on NHE-1 inhibitory activity of (5-arylfuran-2-ylcarbonyl)guanidines, previously identified as potent NHE-1 inhibitors, was investigated. The introduction of amine or alkyl groups at the 3-position of the furan ring, next to the acylguanidine moiety, remarkably improves NHE-1 inhibitory potency. Especially the important finding is that 5-(2,5-dichloro)phenyl and 5-(2-methoxy-5-chloro)phenyl derivatives exhibit high NHE-1 inhibitory activities (IC50 0.02 μM) that match those of 3-unsubstituted derivatives.

AROYLFURANES AND AROYLTHIOPHENES

The invention relates to compounds of formula (I) and of formula (II) wherein ring A is a phenyl, pyridine, pyrimidine or pyrazine ring, W and X are carbon or nitrogen, Y is oxygen or sulfur, R0 is different from hydrogen, Rx is -(C=O)R1 or cyano; R1 is hydrogen, optionally substituted hydroxy or optionally substituted amino, and the other substituents are as described in the specification. The invention further relates to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I) and of formula (II), to the use of compounds of formula (I) and of formula (II) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using compounds of formula (I), of formula (II) or of pharmaceutical compositions containing same.

Pyrrole derivatives and medicinal composition

The invention relates to a pharmaceutical composition comprising a pyrrole derivative of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate of either of them, as an active ingredient. STR1 (wherein R1 represents hydrogen or alkoxycar91 bonylamino, R2 represents alkyl, aryl which may be substituted, aromatic heterocyclyl which may be substituted, unsubstituted amino, monoalkylamino, dialkylamino, or cyclic amino which may be substituted; R3 represents cyano or carbamoyl; R4 represents hydrogen or alkyl; E represents alkylene; q is equal to 0 or 1, A represents methyl, aryl which may be substituted, or aromatic heterocyclyl which may be substituted). The pharmaceutical composition of the invention is effective for the treatment of pollakiuria or urinary incontinence.